NEW YORK, April 27, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced
that Dr. Rachel Yehuda appeared at
SXSW for a panel discussion entitled Psychedelics: Rewiring Mental
Health Care. The Company is a proud supporter of Dr. Yehuda's
research. The SXSW panel discussed ongoing clinical trials,
recent medical discoveries, and how psilocybin may be part of the
solution to our mental health crisis. The session is available on
demand at the SXSW website.
As previously noted, there are 45 million Americans with a
mental illness. In recent years, medical professionals have
turned to natural medicine for an answer - and they might have
found it in psilocybin, the psychoactive substance found in magic
mushrooms. Designated as "breakthrough therapy" by the FDA,
psilocybin therapy has the potential to reinvent the paradigm for
treating psychiatric disorders like addiction, PTSD and depression.
The panel discussion allows individuals to listen to experts in all
things mushroom and psychiatry examine the potential of psilocybin
mushrooms in revolutionizing mental healthcare. They discuss
ongoing clinical trials, recent medical discoveries and how the
fungi may be part of the solution to America's mental health
crisis.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anti-cancer therapeutics. The Company's platform consists of
patented technology from leading universities and researchers, and
we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world
renowned educational institutions, including The University of
Texas at
Austin and University of Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer and prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
|
|
Investor
Relations:
|
|
|
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
AIkido Pharma
Inc.:
|
|
|
|
Phone:
212-745-1373
|
|
Email:
investorrelations@aikidopharma.com
|
|
www.aikidopharma.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-announces-dr-rachel-yehudas-appearance-at-sxsw-301278056.html
SOURCE AIkido Pharma Inc.